Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Fastly Inc (FSLY) Price & Performance

DexCom, Inc.Trade
Fastly IncTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Fastly Inc — how do they compare? DexCom, Inc. trades at $84.03 (market cap $31.86B), while Fastly Inc trades at $29.3 (market cap $4.03B). The key difference: DexCom, Inc. is far larger — about 7.9× Fastly Inc's market cap, and Fastly Inc is more actively traded (5,516,495 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Fastly Inc for 26 Days on average.

DXCMFSLY
Market Cap
$31.86B$4.03B
Volume
3,607,0705,516,495
Sector
HealthTechnology
52-Week High
$92.34$33.50
52-Week Low
$54.84$7.86
Typical Hold Time
62 Days26 Days
Enterprise Value
$31.32B$4.09B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.

The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.

Fastly Inc

Fastly (FSLY) trades at $29.52, up 16.75% with strong momentum following recent earnings beats and AI-driven investor optimism. The stock shows bullish technical signals with price above key support levels, while fundamentals reveal improving revenue growth ($624M in 2025) but persistent net losses (-$122M). Recent investor day highlighted ambitious $1.1-1.3B revenue target by 2029, driving positive sentiment despite insider selling activity.

Outlook remains cautiously optimistic with AI infrastructure demand as key catalyst, though profitability concerns and high valuation multiples present risks. Analyst consensus sits at Hold with $28.25 target, suggesting limited near-term upside from current levels. The stock's 164% YTD run faces sustainability questions amid competitive pressures and execution challenges.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DXCM
100% Buy0% Sell
Avg holding period · 62 Days
FSLY
0% Buy100% Sell
Avg holding period · 26 Days

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM →

About Fastly Inc

Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.

Read more on FSLY →